BioSpace News Archive

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, announced that it will host a Town Hall at 1 P.M., Eastern Time on Thursday, March 18, 2021.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March:

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that executives from the Company plan to participate in three virtual healthcare conferences in March.

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company’s single-shot COVID-19 vaccine

Protagonist Therapeutics, Inc. reported that on February 26, 2021, it issued an inducement award to Jami Taylor, the Company’s recently hired Vice President, Corporate Affairs, in accordance with the terms of Ms.

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration, FDA, has approved PEPAXTO® (

XPhyto Therapeutics Corp. at the request of IIROC and the Canadian Securities Exchange is providing additional comments to its news release and list of third-party providers dated January 22, 2021 with regards to recent promotional and investor relations activity provided by said third-parties, in particular a newsletter published by WallStreetAlerts, on behalf of the Company.

Graystone Company, Inc. (OTC: GYST) announced today that it has completed the reverse merger with NutraGyst, Inc.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

The American Cancer Society is proud to announce the addition of four stellar community leaders to join the Illinois Area Board. Ken Hallman, John Greene, Carlos Cata, and Megan McNerney, M.D., Ph.D.